Informações:
Falhas:
ID
19561
Descrição
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00258960
Link
https://clinicaltrials.gov/show/NCT00258960
Palavras-chave
Versões (1)
- 10/01/2017 10/01/2017 -
Transferido a
10 de janeiro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00258960
Eligibility Breast Cancer NCT00258960
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00258960
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Informed Consent
Item
patients must sign an informed consent before of especific procedures of clinical trial.
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma | erbB-2 Receptor Overexpression
Item
patients with histologically confirmed breast cancer and overexpression of her2neu.
boolean
C0678222 (UMLS CUI [1])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
Age
Item
age> 18 years.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog equal or < 2.
boolean
C1520224 (UMLS CUI [1])
Chemotherapy Neoplasm Metastasis
Item
patients have not been treated previously with chemotherapy for metastatic disease.
boolean
C0392920 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
Measurable lesion Quantity
Item
patients must have at least one measurable lesion according to recist criteria.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Organ function Adequate Chemotherapy
Item
patients should have an adequate organ function to tolerate chemotherapy.
boolean
C0678852 (UMLS CUI [1,1])
C0205411 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0205411 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
Hypersensitivity Investigational New Drugs
Item
patients with hypersensitivity reactions to any of the medications of the clinical trial.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
patients who are pregnant or lactating are not eligible.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Liver disease
Item
hepatic disease.
boolean
C0023895 (UMLS CUI [1])
Communicable Disease Uncontrolled
Item
not controlled active infection
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
Metastatic malignant neoplasm to brain Symptomatic
Item
symptomatic metastatic brain cancer
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
Adjuvant therapy Anthracyclines | Doxorubicin Dose Accumulation | Epirubicin Dose Accumulation
Item
previous adyuvant treatment with antrhacyclines with a total accumulated dose > 300 mg/m2 (doxorubicin) or > 600 mg/m2 (epirubicin)
boolean
C0677850 (UMLS CUI [1,1])
C0282564 (UMLS CUI [1,2])
C0013089 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C4055506 (UMLS CUI [2,3])
C0014582 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C4055506 (UMLS CUI [3,3])
C0282564 (UMLS CUI [1,2])
C0013089 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C4055506 (UMLS CUI [2,3])
C0014582 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C4055506 (UMLS CUI [3,3])